The potential effect of onartuzumab , when administered with or without bevacizumab in combination with weekly paclitaxel , on the corrected QT interval ( QTc ) and other electrocardiogram ( ECG ) parameters , was investigated in a randomized , phase 2 study OAM4861g of first - or second-line therapy in patients with locally recurrent or metastatic triple-negative breast cancer .